Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries

Health Affairs

Volumn 30, Issue 8, 2011, Pages 1529-1538

  Danzon, Patricia M ^a   Towse, Adrian ^b   Mulcahy, Andrew W ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b IMS Health Economics Consulting   (United Kingdom)

^c RAND CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ARTICLE; ASIA; CONSUMER; COST EFFECTIVENESS ANALYSIS; DRUG COST; EUROPE; HEALTH; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; INCOME; INVESTMENT; LOWEST INCOME GROUP; MEDICINE; PROFIT; RESEARCH; WESTERN HEMISPHERE; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEE; INSURANCE;

COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; PRESCRIPTION FEES;

EID: 84855167656     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2010.0902     Document Type: Article

References (16)

1. Danzon PM, Towse AK, Mestre-Ferrandiz J. Value-based differential pricing: setting optimal prices for drugs cross-nationally. Cambridge (MA): National Bureau of Economic Research; forthcoming. (NBER Working Paper).
2. Danzon PM, Mulcahy AW, Towse AK. Pharmaceutical prices in emerging markets: effects of income, competition, and procurement. Cambridge (MA): National Bureau of Economic Research; 2011 Jun. (NBER Working Paper No. 17174).
3. Garrison LP Jr., Lubeck D, Lalla D, Paton V, Dueck A, Perez EA. Costeffectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007;110:489-98.
4. Lakdawalla D, Sood N. Innovation and the welfare effects of public drug insurance. J Public Econ. 2009; 93(3-4):541-8.
5. Jena AB, Philipson TJ. Costeffectiveness analysis and innovation. J Health Econ. 2008;27(5): 1224-36.
6. Garber AM, Sox HC. The role of costs in comparative effectiveness research. Health Aff (Millwood). 2010;29(10):1805-11.
7. Neumann PJ, Greenberg D. Is the United States ready for QALYs? Health Aff (Millwood). 2009; 28(5):1366-71.
8. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs-evidence from twenty-five major markets in the 1990s. Health Econ. 2005;14(3): 269-92.
9. Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat. 2007;89(1):88-99.
10. Danzon PM, Epstein AJ. Effects of regulation on drug launch and pricing in interdependent markets. Cambridge (MA): National Bureau of Economic Research; 2008 May. (NBER Working Paper No. 14041).
11. Flynn S, Hollis A, Palmedo M. An economic justification for open access to essential medicine patents in developing countries. J Law Med Ethics. 2009;37(2):184-208.
12. For a discussion of originator price increases following generic drugs' entry into the US market, see Frank RG, Salkever DS. Pricing, patent loss, and the market for pharmaceuticals. Southern Econ J. 1992; 59(2):165-79.
13. Danzon PM, Furukawa MF. Crossnational evidence on generic pharmaceuticals: pharmacy vs. physiciandriven markets. Cambridge (MA): National Bureau of Economic Research; forthcoming. (NBER Working Paper No. 17226).
14. IMS Health. MIDAS 2004-08. Danbury (CT): IMS Health; 2008.
15. World Health Organization. Global price reporting mechanism [Internet]. Geneva: WHO; [cited 2011 Jul 20]. Available from: http://www.who.int/hiv/amds/gprm/en/
16. The eleven countries were Algeria, Brazil, China, Egypt, India, Indonesia, Morocco, the Philippines, South Africa, and Thailand, plus French West Africa-an aggregation constructed by IMS Health comprising ten countries in sub-Saharan Africa (Benin, Burkina Faso, Cameroon, Côte d'Ivoire, Gabon, Guinea, Mali, Republic of the Congo, Senegal, and Togo).